Home » Newsletters » BioWorld Science

BioWorld Science

June 7, 2019

View Archived Issues

Aqualung Therapeutics wins award to support development of therapies for ARDS

In vitro study identifies factors responsible for the SPARCL of youth

AMG-172 investigated in relapsed/refractory renal cell carcinoma

Axovant presents 6-month follow-up data from first cohort of SUNRISE-PD study

Enlivex Therapeutics provides clinical update for its OTS Allocetra therapy for severe sepsis

Early signals of clinical activity observed in phase I study of KX2-391 in patients with psoriasis

TAXIS Pharmaceuticals identifies new antibacterials

Principia Biopharma patents proteasome subunit beta type-8 and/or beta type-9 inhibitors

The University of Kansas, Victoria Link disclose mu-opioid receptor agonists

Bristol-Myers Squibb presents Toll-like receptor 7, 8 and/or 9 antagonists

MAP3K5 inhibitors discovered at Sidecar Therapeutics

Apalutamide + ADT in mCSPC: first data from the TITAN study presented

Nasally administered olanzapine INP-105 more rapidly absorbed than other formulations

Phase III ASCERTAIN trial of ASTX-727 in MDS or CMML meets primary endpoint

Purdue initiates phase I study of nalmefene hydrochloride for emergency treatment of opioid overdose

Goldfinch begins first-in-human study of GFB-887 for kidney disease

NeRRe reports data from phase IIb study of orvepitant in chronic cough

Novartis presents data from LINC3 study on osilodrostat in patients with Cushing's disease

American BriVision reports phase II data on ABV-1504 for major depressive disorder

Anti-ENG antibody-drug conjugates show preclinical efficacy for the treatment of Ewing's sarcoma

Identification and characterization of a fluorinated indole-imidazole as a 5-HT7 receptor agonist

Novel berberine-metformin hybrid with improved antihyperlipidemic effect for type 2 diabetes

Phase I results presented for ERK-1/2 inhibitor LY-3214996 in advanced cancer

Preliminary activity seen with estrogen receptor alpha antagonist H3B-6545 in breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...